3 Stocks Pushing The Drugs Industry Downward
All three major indices are trading down today with the
Dow Jones Industrial Average
(
^DJI
) trading down 86 points (-0.5%) at 18,509 as of Thursday, July 21, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,295 issues advancing vs. 1,607 declining with 160 unchanged.
The Drugs industry currently sits up 0.7% versus the S&P 500, which is down 0.3%. Top gainers within the industry include
(
), up 6.7%,
(
), up 2.3% and
(
), up 2.0%.
TheStreet would like to highlight 3 stocks pushing the industry lower today:
3.
(
) is one of the companies pushing the Drugs industry lower today. As of noon trading, Illumina is down $1.58 (-1.0%) to $151.01 on light volume. Thus far, 382,618 shares of Illumina exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $150.30-$152.67 after having opened the day at $152.46 as compared to the previous trading day's close of $152.59.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. Illumina has a market cap of $21.9 billion and is part of the health care sector. Shares are down 20.5% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Illumina a buy, 1 analyst rates it a sell, and 10 rate it a hold.
TheStreet Ratings rates
Illumina
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is down $1.01 (-2.1%) to $46.19 on average volume. Thus far, 2.5 million shares of Mylan exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $45.97-$47.69 after having opened the day at $47.06 as compared to the previous trading day's close of $47.20.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $22.8 billion and is part of the health care sector. Shares are down 12.7% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Mylan a buy, no analysts rate it a sell, and 5 rate it a hold.
TheStreet Ratings rates
Mylan
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is down $1.49 (-0.8%) to $193.94 on light volume. Thus far, 507,270 shares of Shire exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $193.57-$195.50 after having opened the day at $194.39 as compared to the previous trading day's close of $195.43.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Shire has a market cap of $37.9 billion and is part of the health care sector. Shares are down 4.7% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Shire
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).